4ZE0

Saccharomyces cerevisiae CYP51 (Lanosterol 14-alpha demethylase) Y140F mutant complexed with Voriconazole


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.239 
  • R-Value Work: 0.192 
  • R-Value Observed: 0.194 

wwPDB Validation 3D Report Full Report


This is version 1.5 of the entry. See complete history


Literature

Triazole resistance mediated by mutations of a conserved active site tyrosine in fungal lanosterol 14 alpha-demethylase.

Sagatova, A.A.Keniya, M.V.Wilson, R.K.Sabherwal, M.Tyndall, J.D.Monk, B.C.

(2016) Sci Rep 6: 26213-26213

  • DOI: 10.1038/srep26213
  • Structures With Same Primary Citation

  • PubMed Abstract: 
  • Emergence of fungal strains showing resistance to triazole drugs can make treatment of fungal disease problematic. Triazole resistance can arise due to single mutations in the drug target lanosterol 14α-demethylase (Erg11p/CYP51). We have determined ...

    Emergence of fungal strains showing resistance to triazole drugs can make treatment of fungal disease problematic. Triazole resistance can arise due to single mutations in the drug target lanosterol 14α-demethylase (Erg11p/CYP51). We have determined how commonly occurring single site mutations in pathogenic fungi affect triazole binding using Saccharomyces cerevisiae Erg11p (ScErg11p) as a target surrogate. The mutations Y140F/H were introduced into full-length hexahistidine-tagged ScErg11p. Phenotypes and high-resolution X-ray crystal structures were determined for the mutant enzymes complexed with short-tailed (fluconazole and voriconazole) or long-tailed (itraconazole and posaconazole) triazoles and wild type enzyme complexed with voriconazole. The mutations disrupted a water-mediated hydrogen bond network involved in binding of short-tailed triazoles, which contain a tertiary hydroxyl not present in long-tailed triazoles. This appears to be the mechanism by which resistance to these short chain azoles occurs. Understanding how these mutations affect drug affinity will aid the design of azoles that overcome resistance.


    Related Citations: 
    • Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer.
      Monk, B.C., Tomasiak, T.M., Keniya, M.V., Huschmann, F.U., Tyndall, J.D., O'Connell, J.D., Cannon, R.D., McDonald, J.G., Rodriguez, A., Finer-Moore, J.S., Stroud, R.M.
      (2014) Proc Natl Acad Sci U S A 111: 3865

    Organizational Affiliation

    Department of Oral Sciences, University of Otago, Dunedin, New Zealand.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Lanosterol 14-alpha demethylase
A
539Saccharomyces cerevisiae (strain YJM789)Mutation(s): 1 
Gene Names: ERG11SCY_2394
Membrane protein
inferred by homology
Group: 
MONOTOPIC MEMBRANE PROTEINS
Sub Group: 
Cytochromes P450
Protein: 
Lanosterol 14α-demethylase with bound lanosterol
Find proteins for A6ZSR0 (Saccharomyces cerevisiae (strain YJM789))
Go to UniProtKB:  A6ZSR0
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
HEM
Query on HEM

Download CCD File 
A
PROTOPORPHYRIN IX CONTAINING FE
C34 H32 Fe N4 O4
KABFMIBPWCXCRK-RGGAHWMASA-L
 Ligand Interaction
VOR
Query on VOR

Download CCD File 
A
Voriconazole
C16 H14 F3 N5 O
BCEHBSKCWLPMDN-MGPLVRAMSA-N
 Ligand Interaction
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
VORKd:  30   nM  Binding MOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.20 Å
  • R-Value Free: 0.239 
  • R-Value Work: 0.192 
  • R-Value Observed: 0.194 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 77.22α = 90
b = 66.55β = 98.67
c = 80.9γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
Aimlessdata scaling
PHENIXphasing
MOSFLMdata reduction

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Health Research Council (HRC)New Zealand--
Marsden FundNew Zealand--

Revision History 

  • Version 1.0: 2016-03-30
    Type: Initial release
  • Version 1.1: 2016-06-01
    Changes: Database references
  • Version 1.2: 2016-12-21
    Changes: Non-polymer description, Structure summary
  • Version 1.3: 2017-08-09
    Changes: Data collection, Database references
  • Version 1.4: 2017-11-22
    Changes: Refinement description
  • Version 1.5: 2020-01-01
    Changes: Author supporting evidence